The quiet anniversary passed without fanfare three weeks ago: 25 years since Redcare Pharmacy launched as a digital pioneer in a heavily regulated market. There was no confetti and certainly no rally — the shares have spent the weeks since drifting lower, closing Friday at EUR 59.65 after a 4.7 percent bounce that only partially repaired the damage from earlier losses.
That Friday gain masks a bruising stretch. The stock remains down 7.1 percent on the week and trades a full 34 percent below its twelve-month high of roughly EUR 90, reached last October. Yet it also sits 98 percent above the March trough of around EUR 30 — a range that captures a company oscillating between growth euphoria and growth fatigue, with no fresh narrative to break the cycle.
A quarter-century of normalization, priced in
The journey from regulatory gray zone to established system player is, by any measure, remarkable. What began as a fringe idea — shipping prescription drugs over the internet — has become a group serving 14.7 million active customers, up 9 percent year on year. The regulatory scaffolding has gradually fallen into place: the fixed-fee increase for delivery services that took effect July 1, and the pharmacy operating regulations expected to be finalized in August, which keep operational obligations with pharmacies rather than extending them to logistics providers.
That slow legitimization is the larger story behind the ticker. But the market, as it tends to do, is looking past history to the next chapter — and finding reasons for caution. The operational momentum celebrated three weeks ago has since cost the stock 7.2 percent. The raised full-year guidance delivered roughly two weeks ago — revenue growth now seen between 15 and 17 percent, up from a prior 13 to 15 percent range, with EBITDA margin of 2.5 to 3.0 percent — triggered another 4.4 percent decline. Even the half-year report from about a month ago, showing EUR 1.7 billion in revenue and 19 percent growth, failed to shift the skepticism; shares slid 4.3 percent in its wake.
Growth fatigue sets in
The pattern suggests a market that now takes structural expansion for granted and only reacts to signs of deceleration. Those signs are already on the table: Redcare has flagged markedly slower Rx growth for the second half as the comparison effect from the prescription bonus scheme introduced in 2025 fades. July trends already dipped slightly below the familiar 20 percent threshold, with German non-Rx growth in single digits.
Should investors sell immediately? Or is it worth buying Redcare Pharmacy?
The technical picture reinforces the unease. The 50-day moving average sits at roughly EUR 64.7, comfortably above the current price, while the 200-day average of about EUR 57.1 has already been breached to the downside — a configuration that mirrors the caution running through recent trading data.
Leadership transition adds another layer
Against this backdrop, the operational work continues. Redcare has rolled out a cloud-based time-slot management system from Cargoclix at its Pilsen facility, where around ten trucks are processed daily. The digital slot system aims to cut waiting times at the loading ramp and make delivery scheduling more predictable — a small but telling sign that management is fine-tuning supply chains even as the leadership question dominates headlines.
That question remains the central overhang. Peter Schmid von Linstow is set to take over as CEO on October 1, succeeding Olaf Heinrich, bringing more than two decades of experience building digital platforms at companies including Visable, Parship, eBay and AutoScout24. The extraordinary general meeting to confirm his appointment is scheduled for October 14 at the company’s headquarters in Sevenum.
Until then, investors face a dual uncertainty: whether the transition proceeds smoothly, and whether operational initiatives like the Pilsen logistics upgrade signal a broader efficiency push under new leadership. The shares, meanwhile, continue to trade well below the levels of a more optimistic era — a reminder that for a pioneer that spent 25 years shaping its market, convincing the stock exchange of the next growth phase may prove harder than building the business itself.
Ad
Redcare Pharmacy Stock: Buy or Sell?! New Redcare Pharmacy Analysis from September 5 delivers the answer:
The latest Redcare Pharmacy figures speak for themselves: Urgent action needed for Redcare Pharmacy investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from September 5.
Redcare Pharmacy: Buy or sell? Read more here...
